RecruitingLeukemia
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Eligible age
18–70 yrs
Accepts
All genders
Locations
27 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will compare the effects of Quizartinib versus placebo in combination with chemotherapy in participants with newly diagnosed FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) negative acute myeloid leukemia (AML).
Sponsor: Daiichi Sankyo
Where it's recruiting
Arizona
Goodyear · Phoenix · Tucson
California
Los Angeles · Sacramento · San Francisco · Stanford
Colorado
Denver
Connecticut
New Haven
District of Columbia
Washington D.C.
Florida
Jacksonville · Kissimmee · Tampa
Georgia
Atlanta · Augusta
Illinois
Chicago
Kentucky
Lexington
Louisiana
New Orleans
Maryland
Baltimore
Massachusetts
Boston
Source: ClinicalTrials.gov · NCT06578247 · last updated 2026-04-30